Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™

Author's Avatar
Mar 18, 2019
Article's Main Image

Approximately 159 Fewer Major Adverse Cardiovascular Events per 1000 Patients Studied

Data Show Relative Benefits of Vascepa Usage Grow Over Time

Amarin Schedules Webcast Discussion of Presented Data Today, March 18, 2019 at 4:00-5:00 pm CT

PR Newswire